AcelRx Pharmaceuticals (ACRX) Scheduled to Post Earnings on Monday

AcelRx Pharmaceuticals (NASDAQ:ACRX) will be releasing its earnings data after the market closes on Monday, August 5th. Analysts expect AcelRx Pharmaceuticals to post earnings of ($0.23) per share for the quarter.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The business had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.85 million. On average, analysts expect AcelRx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ:ACRX opened at $2.42 on Friday. The firm has a market capitalization of $190.96 million, a price-to-earnings ratio of -2.99 and a beta of 2.14. The business’s fifty day simple moving average is $2.53. The company has a current ratio of 5.03, a quick ratio of 4.91 and a debt-to-equity ratio of 0.79. AcelRx Pharmaceuticals has a 52 week low of $1.99 and a 52 week high of $5.05.

A number of brokerages have recently commented on ACRX. B. Riley began coverage on shares of AcelRx Pharmaceuticals in a report on Wednesday, April 24th. They set a “buy” rating and a $6.50 price target on the stock. Zacks Investment Research lowered shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 9th. LADENBURG THALM/SH SH reiterated a “buy” rating and set a $10.00 price target on shares of AcelRx Pharmaceuticals in a report on Thursday, May 9th. ValuEngine lowered shares of AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 9th. Finally, Credit Suisse Group restated an “outperform” rating on shares of AcelRx Pharmaceuticals in a report on Wednesday, July 10th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $7.47.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Read More: What are CEFs?

Earnings History for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.